Skip to main content

Table 2 53BP1 protein expression level and correlation with clinico-pathological parameters

From: BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer

  53BP1 protein expression level (Low < 9.6 U / mg Protein, High ≥9.6 pg/mg Protein)
Patients’ characteristics N (%) Low n (%) High n (%) p
Age at diagnosis (years)     1
Median (range) 54 (29–75)    
≤ 54 80 (52.6%) 40 (52.6%) 40 (52.6%)  
> 54 72 (47.4%) 36 (47.4%) 36 (47.5%)  
Menopausal status     0.87
Pre-menopausal 69 (44.7%) 34 (44.7%) 35 (46.1%)  
Post-menopausal 83 (55.3%) 42 (55.3%) 41 (53.9%)  
T classification     0.57
T1 75 (49.3%) 37 (48.7%) 38 (50%)  
T2 73 (48%) 38 (50%) 35 (46.1%)  
T3-4 4 (2.6%) 1 (1.3%) 3 (3.9%)  
N classification     0.015
N0 104 (68.4%) 59 (77.6%) 45 (59.2%)  
N+ 48 (31.6%) 17 (22.4%) 31 (40.8%)  
Histology     0.44
Ductal 117 (77%) 58 (76.4%) 59 (77.6%)  
Lobular 9 (5.9%) 3 (3.9%) 6 (7.9%)  
Other 26 (17.1%) 15 (19.7%) 11 (14.5%)  
Grade     0.46
I / II 1 (0.7%) / 50 (32.9%) 23 (30.3%) 28 (36.8%)  
III 101 (66.4%) 53 (69.7%) 48 (63.2%)  
ER     0.005
Positive 87 (57.2%) 35 (46.1%) 52 (68.4%)  
Negative 65 (42.8%) 41 (53.9%) 24 (31.6%)  
PR     0.013
Positive 59 (38.8%) 22 (28.9%) 37 (48.7%)  
Negative 93 (61.2%) 54 (71.1%) 39 (51.3%)  
HER2     0.73
Positive 48 (31.6%) 25 (32.9%) 23 (30.3%)  
Negative 104 (68.4%) 51 (67.1%) 53 (69.7%)  
Molecular profile grouping     0.022
HER2+ 48 (31.6%) 25 (32.9%) 23 (30.3%)  
HR+/HER2- 57 (37.5%) 21 (27.6%) 36 (47.4%)  
Triple Negative 47 (30.9%) 30 (39.5%) 17 (22.4%)  
BRCA1 methylation Status     0.045
Methylated 18 (11.8%) 13 (17.1%) 5 (6.6%)  
Not Methylated 134 (88.2%) 63 (82.9%) 71 (93.4%)  
PARP activity     0.048
≤ 2.6 U/mg Prot 39 (25.6%) 21 (27.6%) 18 (23.8%)  
2.7 - 7 41 (27%) 27 (35.5%) 14 (18.4%)  
7.1 - 14 36 (23.7%) 14 (18.4%) 22 (28.9%)  
> 14 36 (23.7%) 14 (18.4%) 22 (28.9%)